A nanomedicine, chemistry and tumor biology therapeutic recipe made @ UK-Portugal to defeat glioblastoma

Cláudia Martins, Catarina Barbosa, Marco Araújo, Stuart J. Smith, Maria Oliveira, Dimitrios Lamprou, Ruman Rahman, Jonathan W. Aylott, Bruno Sarmento

Research output: Contribution to conferenceAbstractpeer-review

Abstract

The 5-year survival of glioblastoma (GBM) patients is limited to a dismal
5%, highlighting the need to advance more effective therapies. GBM tissue abnormally overexpresses the L-type amino acid transporter 1 (LAT1), for which L-histidine (His) is an inexpensive and powerful targeting ligand. Thus, we propose the chemical modification of a conventional chemo-immunogenic drug, docetaxel, into a nanomedicine with surface-His (nano-DTX-His) to target GBM tissue via LAT1 adhesive binding and further augment localized cell death. Since nano-DTX-His cannot be used for IV therapies due its inability to cross the blood-brain barrier (BBB) per se, we further propose its modification with an
acid-cleavable Angiopep-2 layer (nano-DTX-His-clv-Angiopep2) to favor BBB
translocation. It is of important note that the choice of DTX is based on its IC50, which is around 20.000-times lower than the standard temozolomide (in https://www.cancerrxgene.org/).
Original languageEnglish
Publication statusAccepted - 01 Sep 2021
Event2021 UKICRS Virtual Symposium -
Duration: 13 Oct 202113 Oct 2021
https://www.ukicrs.org/2021-virtual-symposium.html

Conference

Conference2021 UKICRS Virtual Symposium
Period13/10/202113/10/2021
Internet address

Keywords

  • Nanomedicine
  • Microfluidics
  • TUMOR
  • Glioblastoma

Fingerprint

Dive into the research topics of 'A nanomedicine, chemistry and tumor biology therapeutic recipe made @ UK-Portugal to defeat glioblastoma'. Together they form a unique fingerprint.

Cite this